BRCA1 and prostate carcinoma: Co‐administration of HDAC and PARP inhibitors can synergistically reduce BRCA1 expression in prostate cancer[33] or induce DNA damage in Ewing sarcoma models,[45] such studies have focused on synthetic lethality and cell cycle arrest, with limited attention to immune modulation.